Denali Therapeutics (DNLI) – Investment Analysts’ Weekly Ratings Changes

A number of research firms have changed their ratings and price targets for Denali Therapeutics (NASDAQ: DNLI):

  • 1/2/2018 – Denali Therapeutics is now covered by analysts at Evercore ISI. They set an “outperform” rating and a $23.00 price target on the stock.
  • 1/2/2018 – Denali Therapeutics is now covered by analysts at Goldman Sachs Group Inc. They set a “neutral” rating on the stock.
  • 1/2/2018 – Denali Therapeutics is now covered by analysts at Morgan Stanley. They set an “overweight” rating and a $25.00 price target on the stock.
  • 1/2/2018 – Denali Therapeutics is now covered by analysts at JPMorgan Chase & Co.. They set an “overweight” rating and a $24.00 price target on the stock.

Shares of Denali Therapeutics Inc (NASDAQ DNLI) opened at $16.13 on Wednesday. The stock has a market cap of $1,420.00 and a PE ratio of -15.66. Denali Therapeutics Inc has a 1-year low of $14.72 and a 1-year high of $22.95.

In other Denali Therapeutics news, major shareholder Douglas K. Bratton bought 275,000 shares of Denali Therapeutics stock in a transaction dated Tuesday, December 12th. The stock was purchased at an average price of $18.00 per share, for a total transaction of $4,950,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Denali Therapeutics Inc is a biotechnology company. The Company is focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and others. The Company is developing a diversified portfolio of therapeutics, based on scientific insights into the genetic causes and biological processes underlying neurodegenerative disease.

Receive News & Ratings for Denali Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply